Coronary vasoconstrictor effects of atriopeptin II

Science. 1985 Nov 1;230(4725):558-61. doi: 10.1126/science.2931801.

Abstract

Atrial natriuretic peptides lower arterial pressure, cardiac filling pressure, and cardiac output. In isolated, Langendorff-perfused guinea pig hearts, atriopeptin II, the 23-amino acid atrial natriuretic peptide, is also a potent coronary vasoconstrictor. The median effective dose for atriopeptin II in guinea pig hearts is 26 nanomoles, the threshold constrictor dose is 5 nanomoles, and flow nearly ceases at a dose of 100 nanomoles in perfused hearts at constant pressure. Similar concentrations of atriopeptin II also cause coronary vasoconstriction in rat and dog heart preparations. The disulfide bridge is necessary for vasoconstrictor activity; reduction of this bridge abolishes the activity, as it does the other biological activities of atrial natriuretic peptides.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine / pharmacology
  • Animals
  • Atrial Natriuretic Factor / pharmacology*
  • Coronary Circulation / drug effects*
  • Dose-Response Relationship, Drug
  • Guinea Pigs
  • Norepinephrine / pharmacology
  • Perfusion
  • Regional Blood Flow / drug effects
  • Vasoconstriction / drug effects*
  • Verapamil / pharmacology

Substances

  • Atrial Natriuretic Factor
  • Verapamil
  • Adenosine
  • Norepinephrine